title: Myelosuppression by sunitinib is flt-3 genotype dependent.
authors.forename: N P
authors.initials: NP
authors.lastname: van Erp
authors.forename: R H J
authors.initials: RH
authors.lastname: Mathijssen
authors.forename: A A
authors.initials: AA
authors.lastname: van der Veldt
authors.forename: J B
authors.initials: JB
authors.lastname: Haanen
authors.forename: A K L
authors.initials: AK
authors.lastname: Reyners
authors.forename: K
authors.initials: K
authors.lastname: Eechoute
authors.forename: E
authors.initials: E
authors.lastname: Boven
authors.forename: J A M
authors.initials: JA
authors.lastname: Wessels
authors.forename: H-J
authors.initials: HJ
authors.lastname: Guchelaar
authors.forename: H
authors.initials: H
authors.lastname: Gelderblom
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007970:Leukopenia / Q000139:chemically induced* / Q000235:genetics*; D011110:Polymorphism, Genetic; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000235:genetics*; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; D000077210:Sunitinib